Home › Funds › ALLIANCEBERNSTEIN L.P. › VRTX

ALLIANCEBERNSTEIN L.P. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

ALLIANCEBERNSTEIN L.P. reported holding 3,019,315 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.35B, representing 0.45% of its reported portfolio and ranking #38 among its reported holdings. ALLIANCEBERNSTEIN L.P. has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.02M sh
Reported value held$1.35B
Portfolio Weight0.45%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ALLIANCEBERNSTEIN L.P.'s VRTX position evolved

ALLIANCEBERNSTEIN L.P. first disclosed a stake in VRTX in Q3 2023 at 7,526,456 shares (US$2.62B). The position peaked in Q3 2024 at 7,372,767 shares, worth US$3.43B. Across 12 filings, ALLIANCEBERNSTEIN L.P. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,019,315 shares valued at US$1.35B — a reduction of -891,471 shares quarter over quarter.. Notable position changes include a 47% trim in Q4 2024 (shares rose 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.53M $2.62B New
Q4 2023 7.04M $2.86B Reduce
Q1 2024 7.10M $2.97B Add
Q2 2024 7.22M $3.38B Add
Q3 2024 7.37M $3.43B Add
Q4 2024 3.92M $1.58B Reduce
Q1 2025 3.95M $1.92B Add
Q2 2025 4.38M $1.95B Add
Q3 2025 4.52M $1.77B Add
Q4 2025 4.50M $2.04B Reduce
Q1 2026 3.91M $1.77B Reduce
Q2 2026 3.02M $1.35B Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has ALLIANCEBERNSTEIN L.P. held VRTX?

ALLIANCEBERNSTEIN L.P. has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ALLIANCEBERNSTEIN L.P.'s current position in VRTX?

As of Q2 2026, ALLIANCEBERNSTEIN L.P. holds 3.02M shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $1.35B, representing 0.45% of its reported portfolio and ranking #38.

Has ALLIANCEBERNSTEIN L.P. been buying or selling VRTX?

In the latest 13F filing (Q2 2026), ALLIANCEBERNSTEIN L.P. reduced its position in VRTX. The position peaked in Q3 2024 at 7.37M shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.